Champions Oncology Names Brian Alexander to Board as Company Advances Data-Driven Oncology Strategy

Champions Oncology (Nasdaq:CSBR) appointed Brian Alexander, MD, MPH, to its Board of Directors on March 30, 2026, to advance its data-driven translational oncology strategy.

Rhea-AI Summary

Champions Oncology (Nasdaq:CSBR) appointed Brian Alexander, MD, MPH, to its Board of Directors on March 30, 2026, to advance its data-driven translational oncology strategy. His experience in oncology, data science, and drug development supports Champions' effort to connect patient-derived tumor models with molecular and clinical datasets.

The company intends to use advanced analytics and AI to deepen disease insights, accelerate discovery, and improve translational R&D outcomes by linking PDX tumor models with multi-omic and patient data.

Argus Mar 30 session

+1.74% close to close Open Argus

Details

News Market Reaction – CSBR

On Mar 30, the day this news came out, CSBR closed 1.74% above the previous close.

Data tracked by StockTitan Argus for the Mar 30 session.

Historical Context

4 past events · Latest: Mar 12

4 events

1. Mar 12

   Q3 earnings

   24h Move

   +6.3%

   Reported Q3 FY2026 revenue of $16.6M and modestly positive price reaction.

2. Mar 05

   Earnings date

   24h Move

   +2.4%

   Announced timing and call details for upcoming Q3 results.

3. Dec 15

   Q2 earnings

   24h Move

   -13.7%

   Reported record Q2 FY2026 service revenue of $15.0M but shares fell sharply.

4. Dec 08

   Earnings date

   24h Move

   +0.2%

   Set date and access details for Q2 FY2026 earnings release and call.

24h Move is the share-price change in the day after each event; other market factors may also have contributed.

Key Terms

pdx models, multi-omic, ai, translational research

4 terms

pdx models medical

"Champions Oncology is building an integrated platform centered on PDX models, combining patient-derived tumors..."

PDX models are preclinical research tools created by implanting a small sample of a patient’s tumor into a lab animal, usually a mouse, so scientists can watch how the human cancer responds to treatments in a living system. For investors, PDX data matter because they can make a drug’s early testing more realistic than cell dishes alone—like taking a prototype car on a similar road before full production—helping to gauge clinical promise and reduce development risk.

multi-omic medical

"help us better link tumor models with multi-omic and patient data, accelerate discovery..."

Multi-omic describes the combined analysis of different biological data types—such as genes, proteins and small molecules—to get a fuller picture of how living systems work. Think of it like studying a recipe (genes), the ingredients list (proteins) and the final dish (metabolites) together rather than separately. For investors, multi-omic approaches can improve drug discovery, diagnostics and patient targeting, potentially raising the odds of successful, marketable products.

ai technical

"This foundation enables the use of advanced analytics and AI to generate deeper insights into disease biology..."

Artificial intelligence (AI) is technology that enables machines to mimic human thinking and learning, allowing them to analyze information, recognize patterns, and make decisions. For investors, AI matters because it can improve how businesses operate, create new products, or identify opportunities faster and more accurately than humans alone, potentially impacting company success and market trends.

translational research medical

"its evolution toward a more connected translational research platform."

Translational research turns laboratory discoveries into tests, treatments, or medical products for people, acting as the bridge between basic science and practical use. Like converting a prototype into a store-ready product, it shows whether promising biology can become a safe, regulated, and sellable therapy, diagnostic, or device. For investors, clear translational progress reduces technical and regulatory uncertainty, creates milestone-driven value, and signals when commercial returns might be possible.

AI-generated analysis. How Rhea-AI works. Not financial advice.

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

Appointment underscores Champions' focus on leveraging clinically relevant data to power next-generation oncology R&D

HACKENSACK, NJ / ACCESS Newswire / March 30, 2026 / Champions Oncology, Inc. (Nasdaq:CSBR), a leading translational oncology research organization, today announced the appointment of Brian Alexander, MD, MPH, to its Board of Directors. Dr. Alexander brings extensive experience at the intersection of oncology, data science, and drug development, having held senior leadership roles at organizations including Valo Health, Flagship Pioneering, and Foundation Medicine. His addition supports Champions' strategy to expand the use of clinically relevant data to inform drug discovery and development.

Champions is advancing an approach that connects its portfolio of patient-derived tumor models with molecular and clinical datasets to drive more informed decision-making across the drug development lifecycle. This foundation enables the use of advanced analytics and AI to generate deeper insights into disease biology and improve R&D outcomes. Dr. Alexander's appointment reflects the Company's continued investment in this capability and its evolution toward a more connected translational research platform.

"Brian brings a unique combination of clinical, scientific, and data-driven leadership experience that aligns closely with where Champions is heading," said Ronnie Morris, Chairman of the Board at Champions Oncology. "As we continue to expand our data capabilities, his perspective will help us better link tumor models with multi-omic and patient data, accelerate discovery, and support more efficient clinical development."

"I'm excited to join Champions at an important point in its evolution," said Dr. Alexander. "The ability to connect well characterized tumor models with rich datasets creates a powerful opportunity to deepen our understanding of disease and enable more informed therapeutic development. I look forward to working with the team to advance this approach."

Champions Oncology is building an integrated platform centered on PDX models, combining patient-derived tumors with comprehensive molecular and clinical data. This approach enhances its ability to support partners across the oncology R&D continuum, from early discovery through translational development, with a more data-informed and analytically driven strategy.

To learn more about how Champions Data Services powers oncology drug discovery, visit: https://www.championsoncology.com/data-ecosystem

About Champions Oncology

Champions Oncology is a global preclinical and clinical research services provider that offers end-to-end oncology R&D solutions to biopharma organizations. With the largest and most annotated bank of clinically relevant patient-derived xenograft (PDX) and primary hematological malignancy models, Champions delivers innovative, highest-quality data through proprietary in vivo and ex vivo platforms. Utilizing its large portfolio of cutting-edge bioanalytical platforms, groundbreaking data platform and analytics, and scientific excellence, Champions enables the advancement of preclinical oncology drug discovery and development programs worldwide. For more information, please visit www.ChampionsOncology.com.

Contact:
Gavin Cooper - Vice President of Global Marketing
gcooper@championsoncology.com
+1 (518) 488 9062

SOURCE: Champions Oncology, Inc.

View the original press release on ACCESS Newswire

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

Who is Brian Alexander and why did Champions Oncology (CSBR) add him to the board on March 30, 2026?

Dr. Brian Alexander is an oncology and data-science leader with experience at Valo Health, Flagship Pioneering, and Foundation Medicine. According to Champions, his background supports linking tumor models with molecular and clinical datasets to accelerate translational drug discovery and development.

What strategic role will Brian Alexander play at Champions Oncology (CSBR)?

He will advise on integrating clinical and molecular data with Champions' PDX models to inform drug development decisions. According to Champions, his role focuses on expanding data capabilities, advanced analytics, and AI-driven insights across the R&D lifecycle.

How does Champions Oncology (CSBR) plan to use patient-derived tumor models after this board appointment?

Champions plans to connect PDX models with comprehensive molecular and clinical datasets to improve translational research. According to Champions, this connected platform aims to generate deeper disease biology insights and support partners from discovery through clinical development.

Will Brian Alexander's appointment change Champions Oncology's (CSBR) use of AI and analytics?

The appointment underscores a push to expand AI and analytics around tumor models and datasets. According to Champions, his data-driven expertise will help scale advanced analytics to produce more actionable insights for oncology R&D.

Does Brian Alexander's background suggest new partnerships or capabilities for Champions Oncology (CSBR)?

His experience at organizations focused on data-enabled drug development suggests enhanced data strategy and partnerships may follow. According to Champions, his addition supports evolving the company toward a more connected translational research platform.

Where can investors learn more about Champions Oncology's (CSBR) data-driven platform and services?

Investors can review Champions' description of its integrated PDX and data ecosystem on the company's website. According to Champions, the Data Services section explains how linked tumor models, molecular, and clinical data power oncology discovery.